Published: 2024-07-01 July 01, 2024 08:00 AM Eastern Daylight Time – Funding will advance development of Rejuvenate’s one-time gene therapy RJB-0402 for the treatment of desmoplakin gene variant arrhythmogenic cardiomyopathy SAN DIEGO–(BUSINESS WIRE)–Rejuvenate Bio, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M grant to complete IND-enabling activities...Read More
Published: 2024-06-04 Cecil Farley who has an artificial cornea in his right eye Credit: PA A 91-year-old man has made history by becoming the first patient in England to receive an artificial cornea. Cecil Farley faced a year-long wait for sight-saving surgery after a human cornea transplant failed, but his surgeon offered him the chance to...Read More
May 2024 StemCyte CEO Tong-Young Lee PhDTong-Young Lee, PhD, is a modest man who will repeatedly tell you that he “was lucky”, when it is clear that much of his success is the result of brilliance and hard work. Tong-Young Lee grew up in Taiwan and earned a PhD in pathology from Taiwan National...Read More
Published: 2024-05-23 NEWS PROVIDED BY StemCyte May 23, 2024, 11:47 ET BALDWIN PARK, Calif., May 23, 2024 /PRNewswire/ — StemCyte, a leader in cord blood-based regenerative therapeutics in Southern California, is excited to announce the renewal of its partnership with the California State Umbilical Cord Blood Collection Program (CA-UCBCP). In collaboration with UC Davis Health,...Read More
Published: 2024-02-22 February 22, 2024 12:13 PM Eastern Standard Time SAN DIEGO–(BUSINESS WIRE)–Rejuvenate Bio today announced publication of groundbreaking research in the peer-reviewed journal Cellular Reprogramming. The study, titled “Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice,” reveals promising advancements in combating age-related diseases and extending lifespan through cellular rejuvenation....Read More
Published: 2024-02-19 Author: Danny Sullivan | Published on: February 19, 2024 | Last updated: February 19, 2024 Longevity biotech company Rejuvenate Bio has revealed a strategic partnership to advance the development and commercialization of its gene therapy designed to address canine osteoarthritis. The collaboration with an unnamed “global animal health company” aims to combat the...Read More
Tetanti AgriBiotech Inc., an agricultural biotechnology company cultivated by Diamond Biofund (TWSE: 6901), signed the first phase of contract with Indonesian Unigreen Technology International Group to start the construction of an organic waste treatment plant, on the ceremony held at Indonesian Trade and Economic Office in Taipei today (28th). The two parties will use the...Read More
Published: 2023-11-10 Cross-Border Collaboration Facilitates Flagship Biotech Investments Joint News Release Date: November 5th, 2023 Leading Taiwanese and Japanese biotech venture capitals ally. Diamond Biofund from Taiwan and DCI Partners Co., Ltd. (wholly owned by Daiwa Securities Group, referred to as DCI Partners) from Japan jointly announced that the two parties have established a cross-border...Read More
Published: 2023-11-09 Diamond Biofund invests in full speed after its listing in Taiwian Stock Exchange. Following investing in Syncell, Diamond Biofund has announced on Nov. 8th, 2023 a significant addition of US$6.35 million investment in StemCyte to support its novel cell therapy entering into the global market and its successful capital raise of over US$25...Read More
Published: 2023-10-31 Taiwan’s first Taiwan Stock Exchange (TWSE)-listed venture capital firm, Diamond Biofund, has proudly announced a substantial investment of US$4 million in SYNCELL Inc. This investment is intended to facilitate the pilot production of cutting-edge Spatial Biology instruments in Taiwan, preparing for global market entry. Founded by Dr. Chung-Chi Liao, SYNCELL Inc., a spin-off...Read More
